hackint0sh/New-Dataset huggingface dataset:
Intravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties.7-9 It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery.10-13 Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery.14,15 IV methadone has, however, never been compared with IT morphine as a postoperative analgesic.
Our hypothesis is that intravenous (IV) methadone is non-inferior to IT morphine in patients who undergo major abdominal surgery. It offers the advantage of being a noninvasive analgesic, modality that may contribute to decreasing opioid consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery. conditions: Pain, Postoperative studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: a single blind study primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: PARTICIPANT count: 218 type: ESTIMATED name: Methadone name: Morphine measure: Quality of Recovery 15 score measure: Overall Benefits of Analgesic Score (OBAS) measure: morphine milligram equivalent measure: Verbal Rating Scale (VRS) pain scores measure: McGill Pain questionnaire score measure: Verbal Rating Scale (VRS) pain scores sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Virginia city: Charlottesville state: Virginia zip: 22908-0710 country: United States lat: 38.02931 lon: -78.47668 hasResults: False
nctId: NCT06387290 id: 00172836 briefTitle: Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2030-05-01 date: 2030-05-01 date: 2024-04-29 date: 2024-04-29 name: University of Utah class: OTHER name: Rutgers University briefSummary: The primary aim of this implementation-effectiveness trial is to examine the effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) and patient-centered chronic pain management visits in primary care as interventions to reduce chronic pain, improve quality of life, and reduce opioid-related harms among chronic pain patients on long-term opioid therapy. conditions: Chronic Pain conditions: Prescription Opioid Misuse conditions: Substance-Related Disorders conditions: Pain conditions: Narcotic-Related Disorders conditions: Chemically-Induced Disorders conditions: Mental Disorders conditions: Opioid-Related Disorders conditions: Neurologic Manifestations studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Hybrid implementation-effectiveness trial primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Investigators, study staff, and statistician will be blinded to treatment condition. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: Mindfulness Oriented Recovery Enhancement name: Patient-Centered Chronic Pain Management Visits measure: Opioid Misuse measure: Chronic Pain measure: Change in Quality of Life measure: Opioid Dosing measure: Opioid Craving measure: PTSD Symptoms measure: Depression measure: Generalized Anxiety measure: Decentering measure: Mindful Reappraisal of Pain Sensations measure: Savoring measure: Reappraisal sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rutgers University Primary Care Clinics city: New Brunswick state: New Jersey zip: 08901 country: United States name: Thanusha Puvananayagam, MPH role: CONTACT phone: 732-235-4341 email: puvanath@rwjms.rutgers.edu name: Taylor Scott, MSW role: CONTACT phone: 732-235-7453 email: taylor.m.scott@rutgers.edu name: Nina Cooperman, PsyD role: PRINCIPAL_INVESTIGATOR lat: 40.48622 lon: -74.45182 facility: University of Utah Primary Care Clinics city: Salt Lake City state: Utah zip: 84112 country: United States name: Kelly A Hendrickson, MS role: CONTACT phone: 801-585-6354 email: kelly.hendrickson@utah.edu name: Layla Lincoln, BA role: CONTACT phone: 801-581-7508 email: layla.lincoln@utah.edu name: Eric L Garland, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06387277 id: RV1551P20220376 briefTitle: Re-epithelialization Efficacy Evaluation of Cosmetic Product RV1551P vs Non-treated Forearm of Healthy Adult Women overallStatus: COMPLETED date: 2022-09-19 date: 2022-12-12 date: 2022-12-12 date: 2024-04-29 date: 2024-04-29 name: Pierre Fabre Dermo Cosmetique class: INDUSTRY briefSummary: The aim of this study was to evaluate the impact of the product RV1551P GB3224 on skin microbiota during wound healing process, based on swab samples collected from lesion areas using an epidermally ablated skin model of erbium YAG laser. conditions: Healthy studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 21 type: ACTUAL name: RV1551P GB3224 measure: Time to re-epithelialization as assessed by in vivo examination by the investigator and standardized photographs taken with a C Cube Camera® measure: Skin microbiota diversity from swab samples. measure: Skin microbiota composition from swab samples. measure: Metabolomic analysis from swab samples sex: FEMALE minimumAge: 20 Years maximumAge: 45 Years stdAges: ADULT facility: Skin Research Centre city: Toulouse state: Haute-Garonne zip: 31300 country: France lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06387264 id: 2022PHC032 briefTitle: Compont - Varicose Veins of the Lower Extremities overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-11 date: 2024-04 date: 2024-12 date: 2024-04-29 date: 2024-04-29 name: Peking University People's Hospital class: OTHER name: Peking University First Hospital name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine name: First Affiliated Hospital Xi'an Jiaotong University name: Liaocheng People's Hospital name: The Second Affiliated Hospital of Chongqing Medical University briefSummary: The purpose of this clinical trial is to evaluate the effectiveness and safety of Medical Adhesive produced by Beijing Compont Medical Devices Co., Ltd. in the treatment of varicose veins in the lower extremities.
Return to the hospital at 1, 12, and 24 weeks postoperatively for Doppler ultrasound, and at 4, 12, 24 weeks postoperatively for venous scoring. conditions: Varicose Veins of Lower Limb studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 188 type: ACTUAL name: Medical Adhesive name: ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter measure: Clinical success rate measure: Technical success rate measure: Target vascular closure rate at 12 weeks after operation. measure: Clinical signs measure: Venous Clinical Severity Score (VCSS) measure: Aberdeen Varicose Vein Questionnaire (AVVQ) measure: Operation duration measure: Evaluation of product performance sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University People's Hospital city: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06387251 id: 2023-11-437-0003 briefTitle: Assess the Effects of a 30 Day-wellness Program on Digestive Health, Weight and Overall Well-being overallStatus: COMPLETED date: 2024-01-29 date: 2024-02-29 date: 2024-02-29 date: 2024-04-29 date: 2024-04-29 name: Peryam & Kroll Research Corporation class: OTHER name: Alticor Inc. briefSummary: The digestive system is a pivotal component of human health, playing a crucial role in the absorption of nutrients, elimination of waste, and even influencing mental well-being. Poor digestive health can significantly impact one's quality of life and overall well-being. Issues such as bloating, constipation, or imbalanced gut microbiome can affect one's overall well-being. Moreover, the gut-brain connection underscores how digestive health can affect mental well-being. The gut can contribute to serotonin and energy production thus influencing one's mood, energy levels and cognitive functions, affecting one's emotional stability. Additionally, inadequate nutrient absorption from an imbalanced digestive system may lead to suboptimal health, weakening the body and causing fatigue. Overall, maintaining good digestive health is crucial not only for physical comfort but also for normal metabolism, immune function, cognitive abilities, sleep and skin health, ultimately enhancing the overall quality of life. Products designed by the sponsor contains a blend of ingredients recognized for their potential benefits in promoting digestive health (including prebiotics, probiotics, postbiotics, plant-based extracts and plant-based protein). Furthermore, it is well established in the literature that diet, exercise, hydration and mindfulness all impact our gut health and overall well-being. Therefore, this scientific study seeks to validate the efficacy of the combination of products and life-style changes by assessing its impact on gut health and related health aspects like weight, metabolic health, fitness level, energy/fatigue levels, satiety/hunger, food cravings, cognitive abilities and overall well-being. conditions: Digestive Health studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 150 type: ACTUAL name: 30 day wellness program measure: Bristol Stool Scale measure: Digestive symptom frequency questionnaire measure: Waist Circumference measure: Improvements in sleep measure: Improvements in stress measure: Fitness Level measure: Satiety Responsiveness and Hunger measure: Craving Intensity measure: Cognitive Abilities measure: Fatigue measure: Skin Appearance measure: General Health measure: Program Feedback sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wilkins Research city: Chattanooga state: Tennessee zip: 37421 country: United States lat: 35.04563 lon: -85.30968 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-12-11 uploadDate: 2024-03-07T13:19 filename: ICF_000.pdf size: 144142 hasResults: False
nctId: NCT06387238 id: PSMA-mHSPC briefTitle: Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2026-06-30 date: 2024-04-29 date: 2024-04-29 name: Peking University First Hospital class: OTHER briefSummary: 1. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a PSMA PET whole-body tumor burden classification was constructed to guide treatment and evaluate prognosis.
2. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a multivariable model will be constructed using quantitative parameters of PSMA PET/CT imaging, pre-treatment gene status, PSA, GS/ISUP and other clinical pathological parameters to further achieve accurate patient classification, guide treatment, and evaluate prognosis. conditions: Prostate Adenocarcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Patients With Metastatic Hormone Sensitive Prostate Cancer, will receive pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy. primaryPurpose: DIAGNOSTIC masking: NONE count: 150 type: ESTIMATED name: PSMA PET/CT measure: rPFS measure: PSA-PFS measure: OS sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06387225 id: RC23_0248 briefTitle: Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients acronym: HYPERION-2 overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2026-12-01 date: 2026-12-01 date: 2024-04-26 date: 2024-04-29 name: Nantes University Hospital class: OTHER briefSummary: Cerebral lesions are responsible for two thirds of deaths in patients admitted to intensive care following cardiac arrest. Patients with neurological lesions should be the priority target for neuroprotective interventions, which are the cornerstone of post-cardiac arrest care (allowing a reduction in the burden of care for patients without this type of lesion). Furthermore, these interventions must be based on a precise assessment of the severity of these brain lesions: carrying out neuro-protective interventions in patients without brain lesions exposes these patients to unnecessary treatment potentially associated with adverse effects without any possible benefit. However, the early assessment of neurological prognosis, particularly on admission to intensive care, is an area where there is little research and where it is not possible to obtain a precise and reproducible assessment. Several tools can be used to assess this prognosis at an early stage: anamnesis and characteristics of the cardiac arrest and the patient's comorbidities, imaging, electrophysiology and biomarkers.
It is important to bear in mind that the aim of this study is not to assess the long-term prognosis of patients suffering cardiac arrest in order to take measures to limit or discontinue active therapies, but simply to provide a reliable tool, simple and quick to use, in order to be able to identify a sub-population of patients who should be the subject of preferential neuro-protection measures, and conversely to simplify management (moderate temperature control, early cessation of sedation, early extubation) for patients with no neurological lesions. conditions: Cardiac Arrest conditions: Neurologic Symptoms conditions: Intensive Care Neurological Disorder studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 608 type: ESTIMATED measure: Dosage of biomarker UCHL-1 (Ubiquitin carboxy-terminal hydrolase L1) at the time of admission to intensive care measure: Dosage of biomarker GFAP (Glial fibrillary acidic protein) at the time of admission to intensive care measure: Neurological outcome at D90 assessed by modified Rankin scale (mRS) measure: Dosage of biomarkers UCHL-1 ((Ubiquitin carboxy-terminal hydrolase L1) and GFAP (Glial fibrillary acidic protein) at the time of admission to intensive care measure: Dosage of biomarkers UCHL-1 ((Ubiquitin carboxy-terminal hydrolase L1) and GFAP( Glial fibrillary acidic protein) at 4 hours for recovery of effective cardiac activity (RACS) measure: Neurological outcome at D90 assessed by modified Rankin scale (mRS) ranging from 0 to 6 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHD Vendée city: La Roche-sur-Yon zip: 85025 country: France name: Gwenael COLIN role: CONTACT lat: 46.66667 lon: -1.43333 facility: APHP - Hôpital Cochin city: Paris zip: 75679 country: France name: Sarah BENGHANEM role: CONTACT lat: 48.85341 lon: 2.3488 facility: CH Saint-Nazaire city: Saint-Nazaire zip: 44600 country: France name: Julien LORBER role: CONTACT lat: 47.28333 lon: -2.2 hasResults: False
nctId: NCT06387212 id: HUI0001 briefTitle: Clinical Efficacy and Safety of 35 kDa Hyaluronan Fragment (HA35) Injection in the Treatment of Skin Problems. overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-05 date: 2024-05 date: 2024-04-26 date: 2024-04-26 name: Nakhia Impex LLC class: INDUSTRY briefSummary: To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems. conditions: Skin Inflammation conditions: Cosmetic Skin studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: 35 kDa hyaluronan fragment HA35 injection measure: A skin dryness scale measure: A fair or smooth skin scale measure: A skin pore size scale measure: A inflammatory skin thick hardness scale measure: An erythema color and area scale measure: Self-satisfaction evaluation sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nahia Impex LLC city: Ulaanbaatar country: Mongolia name: Mizhou Hui role: CONTACT phone: 13484005199 email: mizhou.hui@alumni.utoronto.ca lat: 47.90771 lon: 106.88324 hasResults: False
nctId: NCT06387199 id: 2024-10227 briefTitle: Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide acronym: SEMA SMA overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-07 date: 2026-07 date: 2024-04-26 date: 2024-04-26 name: McGill University Health Centre/Research Institute of the McGill University Health Centre class: OTHER briefSummary: A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose levels. Primarily designed for managing type 1 diabetes, this system has demonstrated significant benefits in previous studies. Yet, despite these advantages, certain challenges persist.
Semaglutide, utilized in treating type 2 diabetes and obesity, is a once-weekly injectable medication that elevates levels of a gastrointestinal hormone known as Glucagon-Like Peptide-1 (GLP-1). This hormone alters gastric emptying, inhibits glucagon release, and reduces appetite. While not officially sanctioned for type 1 diabetes treatment in North America, studies have explored its efficacy as an adjunctive therapy alongside insulin, yielding favorable outcomes in blood glucose regulation. Comparable drugs like liraglutide and exenatide have been employed in type 1 diabetes treatment as well, albeit with less pronounced glucose-regulating effects compared to semaglutide, even in type 2 diabetes.
The goal of this 50-week randomized placebo-controlled crossover 2x4 factorial designed trial is to assess whether commercial automated insulin delivery (AID) systems using rapid-acting insulin with adjunct weekly injections of semaglutide (at the maximally tolerated dose) can replace carbohydrate counting with simple meal announcements (SMA) without degrading glucose control. conditions: Type 1 Diabetes conditions: Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: randomized placebo-controlled crossover 2x3 factorial designed trial primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 26 type: ESTIMATED name: Semaglutide with 4 meal strategies name: Placebo with 4 meal strategies measure: Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo) measure: Percentage of time spent in the range of glucose levels between 3.9 and 7.8 mmol/L measure: Percentage of time spent in glucose levels below 3.9 and 3.0 mmol/L measure: Percentage of time spent in glucose levels above 7.8, 10 and 13.9 mmol/L measure: Mean glucose level measure: Standard deviation of glucose levels as a measure of glucose variability measure: Percentage coefficient of variation of glucose levels measure: Proportions of participants with time in range between 3.9 - 10.0 mmol/L≥ 70% measure: Glycated hemoglobin (HbA1c) measure: Area under the curve 0-2h post meal, 0-3h post peal measure: Average scores between interventions on the Type 1 Diabetes Distress Scale questionnaire measure: Average scores between interventions on the Diabetes Treatment Satisfaction questionnaire measure: Average scores between interventions based on the Hypoglycemic Fear Survey - II measure: Heart rate measure: Blood pressure measure: Measure of body weight measure: Measure of body mass index measure: Measure of waist circumference and hip circumference measure: Measure of waist-to-hip ratio measure: Lipid profile, specifically: LDL-cholesterol, HDL-cholesterol, triglycerides measure: Urine albumin-creatinine ratio sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Research Institute of the McGill University Health Centre city: Montreal state: Quebec zip: H4A 3J1 country: Canada name: Nicholas Sabelli, BSc role: CONTACT phone: (514) 377-9455 email: nicholas.sabelli@mail.mcgill.ca name: Michael Tsoukas, MD role: PRINCIPAL_INVESTIGATOR name: Ahmad Haidar, Ph.D role: SUB_INVESTIGATOR name: Vanessa Tardio, MD role: SUB_INVESTIGATOR lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06387186 id: 2023P003233 briefTitle: Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-03-31 date: 2025-03-31 date: 2024-04-26 date: 2024-04-26 name: Elizabeth Anne Thiele class: OTHER name: Ajinomoto USA, INC. name: Ajinomoto Co., Inc. briefSummary: The main purpose of this study is to evaluate the safety and tolerability of a Leucine-Enriched Essential Amino Acid (LEAA) Powder as an add-on to a classic ketogenic diet (KD) in pediatric and adult patients with refractory epilepsy. conditions: Refractory Epilepsy conditions: Drug Resistant Epilepsy studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Leucine-Enriched Essential Amino Acid powder measure: Number of participants with treatment-related adverse events measure: Number of participants with improved nutritional status as assessed by weight. measure: Number of participants with improved nutritional status as assessed by body mass index (BMI). measure: Number of participants with improved nutritional status as assessed by serum ketone and glucose level. measure: Changes in seizure frequency as assessed by seizure diary. measure: Changes in behavior and cognitive function as assessed by a questionnaire. measure: Changes in seizure severity and overall health as assessed by a questionnaire. sex: ALL minimumAge: 2 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Massachusetts General Hospital city: Boston state: Massachusetts zip: 02114 country: United States name: Lydia Tsega, MD, MPH role: CONTACT phone: 617-726-6524 email: ltsega@mgh.harvard.edu name: Carolyn Wilson role: CONTACT email: cwilson41@mgh.harvard.edu lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06387173 id: 23-001743 id: NCI-2024-01240 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) briefTitle: Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer overallStatus: RECRUITING date: 2024-01-04 date: 2025-01-03 date: 2099-01-03 date: 2024-04-26 date: 2024-04-26 name: Jonsson Comprehensive Cancer Center class: OTHER briefSummary: This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer. conditions: Early Stage Breast Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Non-Interventional Study measure: Prospectively track patients who undergo cryoablation for breast cancer and record post-treatment related events. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UCLA / Jonsson Comprehensive Cancer Center status: RECRUITING city: Los Angeles state: California zip: 90095 country: United States name: Aletta Deranteriassian role: CONTACT phone: 310-206-6114 email: ADeranteriassian@mednet.ucla.edu name: Nimmi S. Kapoor, MD role: CONTACT phone: 818-995-8044 email: nskapoor@mednet.ucla.edu name: Nimmi S. Kapoor, MD role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 hasResults: False